Company Overview
Inhibrx Biosciences, Inc. operates as a clinical-stage biopharmaceutical company dedicated to the development of biologic therapeutics designed to address life-threatening medical conditions. The firm focuses on a specific therapeutic candidate, INBRX-109, which is currently in phase 1 and functions as a tetravalent therapeutic targeting death-receptor 5. This entity functions within the broader Healthcare sector, specifically inside the Biotechnology industry, positioning it as a player in high-risk, high-reward scientific innovation rather than established consumer goods or services. The company's scale is defined by a market capitalization of $922.00M, annual revenue of $1.30M, and an employee base of 109 individuals. These valuation and revenue figures indicate that the company is a small-cap biotechnology firm with limited current income generation, relying heavily on future clinical success to justify its market valuation rather than current cash flows.
Financial Health
The company reported revenue of $1.30M over the trailing twelve months, while recording a net income of $-140,055,008 and an EBITDA of $-132,542,000, revealing a substantial gap between top-line revenue and bottom-line profitability. This significant discrepancy illustrates a cost structure dominated by high fixed expenses, likely driven by research and development expenditures and operational overhead typical of clinical-stage entities. Free cash flow stands at $-84,456,128, indicating that the company is consuming cash reserves to fund its operations and development pipeline rather than generating surplus liquidity for distribution. The margin profile is characterized by a gross margin of 0.0%, an operating margin of -10386.5%, and a profit margin of 0.0%, all of which reflect the pre-revenue or early-revenue stage where costs vastly exceed income before significant product sales occur. Liquidity is supported by cash holdings of $124.22M against total debt of $107.01M, resulting in a debt-to-equity ratio of 1338.82, which suggests a highly leveraged balance sheet relative to equity but provides a net cash position before interest obligations. Short-term liquidity appears robust given a current ratio of 3.93, implying the company possesses more than three times the current assets necessary to cover its current liabilities. Return on equity is listed at -197.8% and return on assets at -51.6%, metrics that reveal management is currently burning through capital to achieve clinical milestones rather than generating returns for shareholders.
Valuation Assessment
The valuation metrics present a complex picture with a P/E Ratio (TTM) of N/A and a forward P/E of -22.62, implying that the market is pricing in a significant turnaround or earnings recovery trajectory that has not yet materialized in historical data. The price-to-book ratio is 115.18, indicating that the market values the company at a massive premium over its tangible book value, likely reflecting high expectations for the success of its pipeline assets. Alternative valuation measures such as a price-to-sales ratio of 709.23 and an EV/EBITDA of -6.83 further emphasize that traditional multiples are distorted by negative earnings and low sales, necessitating a focus on pipeline value rather than current financial performance. The stock has exhibited significant volatility with a 52-week high of $94.56 and a 52-week low of $10.80, placing the current trading price at a level that reflects the wide range of investor sentiment regarding the company's clinical progress. Although the beta value is N/A, the wide spread between the high and low suggests extreme sensitivity to news cycles regarding clinical trial results and regulatory developments.
Growth & Income
Revenue growth year-over-year is -100.0%, while earnings growth year-over-year is N/A, indicating that the company has likely not yet generated positive earnings or that prior period earnings were negligible, making percentage growth calculations undefined or non-applicable. The absence of positive earnings growth relative to revenue stems from the company's fundamental status as a clinical-stage entity where revenue is minimal compared to the heavy investment required for drug development. As a non-dividend payer, the company maintains a dividend yield of N/A and a payout ratio of 0.0%, confirming that it reinvests all available resources and any future earnings back into research and development rather than distributing cash to shareholders. This growth and income profile characterizes Inhibrx Biosciences as a pure-play biotechnology investment where total return potential is entirely dependent on the successful advancement of therapeutic candidates like INBRX-109 through clinical phases and eventual regulatory approval.